Press releases
02 November 2022 | 01:37 PM
Dr Michael Lichtenberg today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22
HORSHAM, UK – 01 Nov 2022 – Veryan Medical Ltd announces that Dr Michael Lichtenberg (Klinikum Hochsauerland, Arnsberg, Germany) today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22 in the Late Breaking Clinical Trials session at VIVA 2022 in Las Vegas, US.
07 October 2022 | 10:24 AM
BioMimics 3D® Vascular Stent System granted Good Design Award 2022
TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., Ltd.) is pleased to announce that the BioMimics 3D Vascular Stent System has been granted a Good Design Award 2022 from the Japan Institute of Design Promotion.
01 May 2022 | 12:49 PM
BioMimics 3D®, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration
HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System.
06 April 2021 | 09:26 AM
Veryan Medical announces multimillion-euro investment in Galway operation
Galway, 06 April 2021 Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent, marketed in Europe and USA to improve blood flow through arteries in the leg.
16 December 2020 | 03:35 PM
First patient enrolment in MIMICS 3D USA
Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study by John H. Rundback MD at NJ Endovascular & Amputation Prevention, NJ.
02 September 2020 | 05:01 PM
First BioMimics 3D US Implant
Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.
01 September 2020 | 08:21 AM
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.
09 June 2020 | 08:45 AM
MIMICS-2 3-year data update
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live.
13 December 2018 | 12:00 AM
December 2018
Otsuka Medical Devices and Veryan joint press release 13 Dec 2018
01 January 2018 | 12:00 AM
January 2018
MIMICS 2 12 month results.
Latest News
Board Announcement – Appointment of new CEO
HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.
36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live.
